Search clinical trials for: Firmagon® (degarelix)

Total 13814 results

Ferring Pharmaceuticals

Completed

Safety and Efficacy of Firmagon® (Degarelix) for Injection

Prostate Cancer

Korea, Republic of
Ferring Pharmaceuticals

Completed

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Advanced Hormone Sensitive Prostate Cancer

Netherlands
Ferring Pharmaceuticals

Completed

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina (FAST AR)

Advanced Hormone Dependent Prostate Cancer

Argentina
United Clinic Management GmbH

Completed

Treatment of Prostate Cancer With Firmagon®

Prostate Cancer

Germany
Ferring Pharmaceuticals

Completed

A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Prostate Cancer

India
Ferring Pharmaceuticals

Completed

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)

Prostate Cancer

France
Ferring Pharmaceuticals

Completed

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Prostate Cancer

Finland, France, Germany
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer (DEGASTIM)

Invasive Ductal Breast Carcinoma

France
Rabin Medical Center
Ferring Pharmaceuticals

Unknown

Cardiovascular Events in GnRH Agonist vs. Antagonist

Prostate Cancer | Cardiac Event | Hormone Sensitive Prostate Cancer

Israel
UNICANCER
Ferring Pharmaceuticals

Active, not recruiting

Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy (GETUG-AFU22)

Adenocarcinoma of Prostate

France
Ferring Pharmaceuticals

Completed

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Prostate Cancer

Taiwan
Ferring Pharmaceuticals

Completed

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Advanced Prostate Cancer

Germany
British Columbia Cancer Agency
Ferring Pharmaceuticals

Unknown

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Prostate Neoplasm

Canada
Ferring Pharmaceuticals

Completed

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

Prostate Cancer

China
Ottawa Hospital Research Institute

Terminated

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (OTT10-06)

Prostatic Neoplasms

Canada
Ferring Pharmaceuticals

Completed

FIRMAGON Intensive Drug Monitoring Protocol

Prostate Cancer

China
University Health Network, Toronto
Bayer; Prostate Cancer Canada

Not yet recruiting

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC)

Prostate Cancer

Canada
Ferring Pharmaceuticals

Completed

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) (DELUTS)

Lower Urinary Tract Symptoms (LUTS)

United States, Canada, Belgium, Czech Republic, Italy, Poland
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

Prostate Cancer

Korea, Republic of
Ferring Pharmaceuticals

Completed

Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

Prostate Cancer

Spain, Netherlands, Belgium, Italy, France, Germany
Turku University Hospital

Not yet recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA)

Prostate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate Cancer

Finland
Mark Stein
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Prostate Cancer

United States, United Kingdom
Ferring Pharmaceuticals

Completed

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
Ferring Pharmaceuticals

Terminated

A Degarelix Trial in Patients With Prostate Cancer

Prostate Cancer

United States, Netherlands, United Kingdom, Hungary, Belgium, Czech Republic, Finland, Germany, Mexico, Poland, Romania, Ukraine, Canada
Ferring Pharmaceuticals

Completed

A Trial of Degarelix in Patients With Prostate Cancer

Prostate Cancer

United States, Canada, Netherlands, United Kingdom, Belgium, Germany, Hungary, Czech Republic, Finland, Mexico, Poland, Romania, Russian Federation, Ukraine
Brown University
Cures Within Reach; Lifespan; Legorreta Cancer Center at Brown University

Recruiting

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (TASUC-Neo)

Urothelial Carcinoma Bladder | Androgen Receptor Positive

United States
Medical University of South Carolina
Ferring Pharmaceuticals

Active, not recruiting

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

Metastatic Prostatic Adenocarcinoma

United States
University of Colorado, Denver

Completed

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

Cognitive Impairment | Menopause | Endothelial Dysfunction | Vascular Stiffness | Estrogen Deficiency

United States
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy (CaNCaP03)

Prostate Cancer

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Urology of Virginia
Ferring Pharmaceuticals

Completed

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

Prostate Cancer

United States
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Ferring Pharmaceuticals
Memorial Sloan Kettering Cancer Center; Duke Clinical Research Institute

Terminated

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE)

Prostate Cancer

United States, France, Canada, Czechia, Finland, Germany, Greece, Poland, Russian Federation, Slovakia, South Africa, United Kingdom
Ferring Pharmaceuticals

Completed

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Prostate Cancer

Belgium, Italy, Sweden, Portugal, Denmark, Finland, Norway, Turkey
Jonsson Comprehensive Cancer Center
GlaxoSmithKline; Novartis; Astellas Pharma Inc; Prostate Cancer Foundation; Medivation...

Active, not recruiting

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Prostate Cancer

United States
Centre Leon Berard

Recruiting

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma (PREFAcE)

Prostate Adenocarcinoma

France
Ferring Pharmaceuticals

Completed

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Prostate Cancer

Spain, France, United States, Greece, United Kingdom, Germany, Netherlands
University of Colorado, Denver

Completed

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

Obesity | Fertility

United States
Centre for Endocrinology and Reproductive Medicine...

Completed

Degarelix in the Treatment of Endometriosis Recurrence

Endometriosis

Albania, Bulgaria, Italy
Centre for Endocrinology and Reproductive Medicine...

Completed

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

PCOS | INFERTILITY | OHSS

Italy
Ferring Pharmaceuticals

Completed

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Prostate Cancer

Netherlands, Belgium, Germany, Russian Federation, South Africa, Hungary, Romania, Poland
Astellas Pharma Inc

Completed

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Prostatic Neoplasms

Japan
Astellas Pharma Inc

Completed

Phase II Study of ASP3550 in Patients With Prostate Cancer

Prostatic Neoplasms

Japan
Ferring Pharmaceuticals

Completed

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

Prostate Cancer

Belgium, Germany, Hungary, Netherlands, Romania, Russian Federation, South Africa
Lund University
Swedish Cancer Foundation; ALF Swedish Government Grant

Completed

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

Prostate Cancer Recurrent

Sweden
Ferring Pharmaceuticals

Completed

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Rabin Medical Center
Ferring Pharmaceuticals

Completed

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

Cardiovascular Diseases | Prostatic Neoplasms

Israel
Ferring Pharmaceuticals

Completed

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Prostate Cancer

Denmark, Sweden, Finland, Hungary, Norway, Romania, Russian Federation

Search clinical trials for: Firmagon® (degarelix)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations